Literature DB >> 111798

Thymidine and thymine in biologic fluids during high-dose infusions of thymidine in mice, monkeys, and man.

D S Zaharko, B J Bolten, T Kobayashi, R G Blasberg, S S Lee, B C Giovanella, J S Stehlin.   

Abstract

Measurements were made to determine if millimolar thymidine (TdR) concentrations, shown to have antitumor activity in vitro, could be attained in vivo. An adaptation of an ion-exclusion liquid chromatography method was used to quantitate TdR and thymine in various biologic fluids. Millimolar concentrations of TdR were attained in plasma of mice, monkeys, and man by constant infusions of large quantities of TdR (approximately 80 g/m2/day). Cerebrospinal fluid concentrations of TdR at equilibrium were one tenth of the plasma concentration in the monkey. The primary route of removal of TdR at these high plasma concentrations is kidney clearance of intact TdR. Metabolism, which plays a major role in the clearance of TdR at micromolar concentrations in plasma, appears to be saturated at millimolar concentrations of TdR.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111798

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  Sensitization of C6 glioma to carboplatin cytotoxicity by hyperthermia and thymidine.

Authors:  J D Cohen; H I Robins; M J Javid
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

2.  Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.

Authors:  G J Peters; C J van Groeningen; E J Laurensse; J Lankelma; A Leyva; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Inhibition of intestinal pyrimidine nucleoside phosphorylases.

Authors:  M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

4.  Computer modeling of the pharmacokinetics of Fluorouracil and thymine and their kinetic interaction in normal dogs.

Authors:  J M Covey; J A Straw
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.